Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer

Polish Journal of Pathology

Volumn 66, Issue 1, 2015, Pages 44-48

  Danilewicz, Marian ^a   Kowska Kanicka, Olga Stasi ^a   Wągrowska Danilewicz, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Ki 67; Prostate cancer; PSA; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; BIOPSY; BLOOD; CANCER GRADING; CASE CONTROL STUDY; CELL PROLIFERATION; CHEMISTRY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; UPREGULATION;

AGED; BIOPSY; CASE-CONTROL STUDIES; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KALLIKREINS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84929403588     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/pjp.2015.51152     Document Type: Article

References (26)

1. Khan S, Jutzy JM, Valenzuela MM, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One 2012; 7: e46737
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
4. Globa T, Saptefrti L, Ceausu R, et al. Mast cell phenotype in benign and malignant tumors of the prostate. Pol J Pathol 2014; 65: 147-153
5. Schröder FH. Screening for prostate cancer. Urol Clin North Am 2003; 30: 239-251
6. Stawerski P, Wagrowska-Danilewicz M, Stasikowska-Kanicka O, et al. Augmented mast cell infiltration and microvessel density in prostate cancer. Contemp Oncol (Pozn) 2013; 17: 378-382
7. Kaczmarczyk K, Dyduch G, Białas M, et al. Frequency of ERG-positive prostate carcinoma in Polands. Pol J Pathol 2013; 64: 175-179
8. Łuczyńska E, Gasińska A, Wilk W. Microvessel density and expression of VEGF in clinically localized prostate cancer. Pol J Pathol 2013; 64: 33-38
9. Lu S, Liu M, Epner DE, et al. Androgen regulation of the cyclin- dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 1999; 13: 376-384
10. Zhang M, Coen JJ, Suzuki Y, et al. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys 2010; 78: 1095-103
11. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54
12. Li F. Survivin study: What is the next wave? J Cell Physiol 2003; 197: 8-29
13. Kishi H, Igawa M, Kikuno N, et al. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 2004; 171: 1855-1860
14. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921
15. Koike H, Sekine Y, Kamiya M, et al. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology 2008; 72: 1229-1233
16. Bialkowska-Hobrzanska H, Driman DK, Fletcher R, et al. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. Can J Urol 2006; 13: 2967-2974
17. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320
18. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341: 452-453
19. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7: 542-547
20. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol 2002; 3: 401-410
21. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64: 7183-7190
22. Chen J, Cui X, Zhou H, et al. Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study. BMC Cancer 2013; 13: 356
23. Li F, Ambrosini G, Chu EY, Plescia J, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584
24. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999; 59: 3143-3151
25. Qin HR, Kim HJ, Kim JY, et al. Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. Cancer Res 2008; 68: 7736-7741
26. Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004; 100: 751-757.